NCT01551212 - Efficacy of Everolimus in Combination With Tacrolimus in Liver Transplant Recipients | Biotech Hunter

Enrollment

339

Participants

Timeline

Start Date

May 24, 2012

Primary Completion Date

August 8, 2017

Study Completion Date

August 8, 2017

Conditions

Liver Transplantation

Interventions

DRUG

Everolimus

tablet containing 0.25mg, 0.5mg, 0.75mg or 1.0mg

DRUG

Tacrolimus

capsule containing 0.5, 1.0, or 5.0mg

DRUG

Corticosteroids

For patients in all groups, corticosteroids were initiated at or prior to the time of transplantation according to local practice. Corticosteroids may have been used for the duration of the study according to the investigator's discretion, but may not have been eliminated sooner than 6 months post-transplantation.

Trial Locations (15)

13353

Novartis Investigative Site, Berlin

20246

Novartis Investigative Site, Hamburg

24105

Novartis Investigative Site, Kiel

30625

Novartis Investigative Site, Hanover

45147

Novartis Investigative Site, Essen

52074

Novartis Investigative Site, Aachen

53105

Novartis Investigative Site, Bonn

55131

Novartis Investigative Site, Mainz

60590

Novartis Investigative Site, Frankfurt

69120

Novartis Investigative Site, Heidelberg

72076

Novartis Investigative Site, Tübingen

81377

Novartis Investigative Site, München

91052

Novartis Investigative Site, Erlangen

93053

Novartis Investigative Site, Regensburg

04103

Novartis Investigative Site, Leipzig